

High-Throughput Screening in ToxCast/Tox21

Keith Houck

*U.S. EPA, National Center for Computational Toxicology
Office of Research and Development*



FutureTox II


Chapel Hill, NC

16-17 January 2014

Outline

- **Need for alternative toxicity testing**
- **Chemical libraries tested**
- **Biological assays for chemical profiling**
- **Tox21 Assay Example**
- **ToxCast Assay Platform Example**
- **Use of Data in Predictive Modeling**
- **Summary of Advantages/Challenges**

Tox21 Vision: Transforming Toxicity Testing



**National Center for Advancing
Translational Sciences (NCATS)**






<http://www.ncats.nih.gov/>


ToxCast /Tox21 Overall Strategy

- **Identify targets or pathways linked to toxicity (AOP focus)**
- **Identify/develop high-throughput assays for these targets or pathways**
- **Develop predictive systems models: *in silico/in vitro* → *in vivo***
- **Use predictive models (qualitative):**
 - **Prioritize chemicals for targeted testing**
 - **Suggest / distinguish possible AOP / MOA for chemicals**
- ***High-throughput Exposure Predictions (ExpoCast)***
- ***High-throughput Risk Assessments (quantitative)***

Testing under ToxCast and Tox21


Chemicals, Data and Release Timelines

Set	Chemicals	Assays	Endpoints	Completion	Available
ToxCast Phase I	 293	~600	~700	2011	Now
ToxCast Phase II	 767	~600	~700	03/2013	12/2013
ToxCast Phase III	 1001	~100	~100	Just starting	2014
E1K (endocrine)	 880	~50	~120	03/2013	12/2013
Tox21	 8,193	~25	~50	Ongoing	Ongoing



Pesticides, antimicrobials, food additives, green alternatives, HPV, MPV, endocrine reference cmpds, other tox reference cmpds, failed drugs, NTP in vivo, EPA high interest compounds, industrial, marketed drugs, fragrances, ...

ToxCast PhI & PhII chemicals: *Spanning diverse inventories of EPA interest*




- 1060 Total chemicals → 2806 total overlaps across 16 diverse inventories (assigned in ACToR)
- Broad diversity of chemical structures & use types
- Large overlap with data-rich inventories


High-Throughput Screening 101 (HTS)



Robots




96-, 384-, 1536 Well Plates




Chemical Exposure




Cell Population




Pathway



Target Biology (e.g.,
Estrogen Receptor)



ToxCast Assays (>700 endpoints)



Assay Provider

ACEA
Apredica
Attagene
BioReliance
BioSeek
CeeTox
CellzDirect
Tox21/NCATS
NHEERL MESC
NHEERL Zebrafish
NovaScreen (Perkin Elmer)
Odyssey Thera
Vala Sciences

Biological Response

cell proliferation and death
cell differentiation
Enzymatic activity
mitochondrial depolarization
protein stabilization
oxidative phosphorylation
reporter gene activation
gene expression (qNPA)
receptor binding
receptor activity
steroidogenesis

Target Family

response Element
transporter
cytokines
kinases
nuclear receptor
CYP450 / ADME
cholinesterase
phosphatases
proteases
XME metabolism
GPCRs
ion channels

Assay Design

viability reporter
morphology reporter
conformation reporter
enzyme reporter
membrane potential reporter
binding reporter
inducible reporter

Readout Type

single
multiplexed
multiparametric

Cell Format

cell free
cell lines
primary cells
complex cultures
free embryos

Species

human
rat
mouse
zebrafish
sheep
boar
rabbit
cattle
guinea pig

Tissue Source

Lung	Breast
Liver	Vascular
Skin	Kidney
Cervix	Testis
Uterus	Brain
Intestinal	Spleen
Bladder	Ovary
Pancreas	Prostate
Inflammatory	Bone

Detection Technology

qNPA and ELISA
Fluorescence & Luminescence
Alamar Blue Reduction
Arraysan / Microscopy
Reporter gene activation
Spectrophotometry
Radioactivity
HPLC and HPEC
TR-FRET

ToxCast Phase II: 1051 Chemicals x 791 Assay Readouts

ACEA: red

Attagene: orange


Apredica: black

BioSeek: green

Novascreen: gray

Tox21: violet

OT: blue



Assays

Chemicals

Table 2 Top 20 most promiscuous chemicals^a

Chemical Name	AC50s		
	Total	<=10μM	<=1μM
Phenylmercuric acetate	90	47	20
Mancozeb	88	41	13
Gentian violet	86	51	5
Sodium dodecylbenzenesulfonate	82	19	0
Tributyltin methacrylate	79	48	12
Tributyltin chloride	77	45	9
Mercuric chloride	73	45	14
Perfluorooctane sulfonic acid	72	13	2
{4-[3-(aminomethyl)phenyl]piperidin-1-yl}{5-[(2-fluorophenyl)ethynyl]furan-2-yl}methanone (pharma)	71	25	4
Dodecylbenzene sulfonate triethanolamine (1:1)	66	7	1
SSR241586 (pharma)	66	30	8
Emamectin benzoate	65	14	2
{4-[5-(aminomethyl)-2-fluorophenyl]piperidin-1-yl}{4-bromo-3-methyl-5-propoxythiophen-2-yl}methanone hydrochloride (pharma)	64	19	2
(1R)-1-[(ethoxycarbonyloxy)ethyl 1-[[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methyl]-2-[[1-(propan-2-yl)piperidin-4-yl]carbonyl]-1H-indole-5-carboxylate hydrochloride(pharma)	63	29	2
Maneb	62	31	16
SSR150106 (pharma)	62	41	13
Didecyl dimethyl ammonium chloride	62	30	2
Zamifenacin (pharma)	60	27	11
SSR125047 (pharma)	59	16	3
Metiram	56	16	4

ToxCast Phase II: 1051 Chemicals x 791 Assay Readouts

ACEA: red

Attagene: orange


Apredica: black

BioSeek: green

Novascreen: gray

Tox21: violet

OT: blue





Assays

Chemicals


Table 3 Top 20 most promiscuous assays ^a				
Assay target	Assay category	AC50s		
		Total	<=10µM	<=1µM
hCYP2C19	CYP	264	144	53
hCYP2C9	CYP	152	81	19
rPBR	Transporter	147	62	18
hPXR	Nuclear receptor (subfamily 1)	140	73	35
hNET	Transporter	136	48	13
hPBR	Transporter	117	36	5
hDAT	Transporter	117	45	7
hCYP1A2	CYP	108	60	16
gDAT	Transporter	98	26	4
h5HT7	GPCR (aminergic)	96	35	13
hGR	Nuclear receptor (subfamily 3)	96	35	6
hOpiate_mu	GPCR (other)	92	27	5
hDRD1	GPCR (aminergic)	89	36	9
rNaCh_site2	Ion channel	87	37	13
hCYP2B6	CYP	81	43	16
gSIGMA_NonSelective	Other	80	31	13
gOpiateK	GPCR (other)	75	18	4
rMAOAC	Other enzyme	73	15	6
hAR	Nuclear receptor (subfamily 3)	73	33	8
hBACE	Protease	73	28	3

Tox21 qHTS Screen


Aryl hydrocarbon Receptor (AhR) Signaling




NCCT/EPA



NIEHS/NTP



NIH/NCATS



FDA

**Environmental
Industrial
Pesticides
Food Use
Drugs
Toxicology**

Chemical Space of Actives

Level 8 Results Summary

No. of HITS **768**

% HITS **9.2**

% Concordance **94.3**

Compound Features

All Compounds
Amino acids
Bases, nucleosides
Benzenes
Carbocycles
Carbohydrates
Elements
Functional groups
Heterocycles
Naphthalenes
Natural products
Peptidomimetics
Pharmacophores
Protective groups
Spacer groups
Compounds Without Features

Frequency





Frequency

764
26
3
676
24
5
31
726
378
55
8
0
747
41
177
6

Z-Score
























-0.465
-0.1735
3.307
0.8749
-0.6666
1.598
-1.759
4.896
0.3566
0.7849
-2.234
-1.701
-1.309
-1.802

-LOG(AC50)



Comparison with actives from AhR
reporter in Attagene assays

Active Structures: Dyes









 DSSTox_GSID_20190	 DSSTox_GSID_20673	 DSSTox_GSID_21082	 DSSTox_GSID_21224	 DSSTox_GSID_21233	 DSSTox_GSID_21234
 DSSTox_GSID_38881	 DSSTox_GSID_41682	 DSSTox_GSID_41706	 DSSTox_GSID_41709	 DSSTox_GSID_41715	 DSSTox_GSID_41719
 DSSTox_GSID_41721	 DSSTox_GSID_41726	 DSSTox_GSID_41728	 DSSTox_GSID_42154	 DSSTox_GSID_44538	 DSSTox_GSID_44663
 DSSTox_GSID_44713	 DSSTox_GSID_44718	 DSSTox_GSID_44904	 DSSTox_GSID_47451		<div> <div>Tox21</div> <div>ATG</div> <div>Tox21 & ATG</div> </div>


Extensively used as colorants in food, cosmetics, waxes, solvents, textiles and so on

Franzosa et al., in prep

Insights in to Mechanisms: BioMap Profiling Assays

Table 1. Diversity 8 panel of BioMAP Systems utilized in this study.

System	Cell Types	Environment	Readouts
3C	 Endothelial cells	IL-1 β + TNF- α + IFN- γ	MCP-1, VCAM-1, ICAM-1, Thrombomodulin, Tissue Factor, E-selectin, uPAR, IL-8, MIG, HLA-DR, Prolif., Vis., SRB (13)
4H	 Endothelial cells	IL-4 + histamine	VEGFR1, P-selectin, VCAM-1, uPAR, Eotaxin-3, MCP-1, SRB (7)
LPS	 Peripheral Blood Mononuclear Cells + Endothelial cells	TLR4	CD40, VCAM-1, Tissue Factor, MCP-1, E-selectin, IL-1a, IL-8, M-CSF, TNF- α , PGE2, SRB (11)
SAG	 Peripheral Blood Mononuclear Cells + Endothelial cells	TCR	MCP-1, CD38, CD40, CD69, E-selectin, IL-8, MIG, PBMC Cytotox., SRB, Proliferation (10)
BE3C	 Bronchial epithelial cells	IL-1 β + TNF- α + IFN- γ	uPAR, IP-10, MIG, HLA-DR, IL-1a, MMP-1, PAI-1, SRB, TGF- β 1, tPA, uPA (11)
HDF3CGF	 Fibroblasts	IL-1 β + TNF- α + IFN- γ + bFGF + EGF + PDGF-BB	VCAM-1, IP-10, IL-8, MIG, Collagen III, M-CSF, MMP-1, PAI-1, Proliferation, TIMP-1, EGFR, SRB (12)
KF3CT	 Keratinocytes + Fibroblasts	IL-1 β + TNF- α + IFN- γ + TGF- β	MCP-1, ICAM-1, IP-10, IL-1a, MMP-9, TGF- β 1, TIMP-2, uPA, SRB (9)
CASM3C	 Coronary artery vascular smooth muscle cells	IL-1 β + TNF- α + IFN- γ	MCP-1, VCAM-1, Thrombomodulin, Tissue Factor, IL-6, LDLR, SAA, uPAR, IL-8, MIG, HLA-DR, M-CSF, Prolif., SRB (14)




← Readout Parameters (Biomarkers) →

Insights in to Mechanisms: BioMap Profiling Assays

Table 1. Diversity 8 panel of BioMAP Systems utilized in this study.

System	
3C	
4H	
LPS	
SAg	
BE3C	
HDF3CGF	
KF3CT	
CASM3C	



Unsupervised Clustering Analysis

- What can we learn about mechanisms of activity through similarity of activity?
- Chemicals analyzed at single conc level to minimize polypharmacology effect
- Self Organizing Maps (SOM): 10X10 Array/100 Clusters
- Identify clusters enriched with chemicals with known activity
- Two examples:

Cluster	Cluster Count	Common Activity	Example Compounds known associations	Example Compounds novel associations
57,67	52	AhR ligands	Hydroquinone 4-Chloro-1,2-diaminobenzene 1,2-Phenylenediamine Fenaminosulf	C.I. Solvent yellow 14
48	27	ER antagonists	Clomiphene citrate Tamoxifen citrate Fulvestrant Raloxifene Tamoxifen 4-Hydroxytamoxifen	Cyclopanine Amiodarone hydrochloride Haloperidol Reserpine Donated pharma: NK1 receptor antagonist Bradykinin B1 receptor antagonist Lipid-lowering agent



All 3 negatives were present at only one conc in the SOM cluster



PAHs from cigarette smoke associated with atherogenesis/thrombosis


Unsupervised Clustering Analysis

- What can we learn about mechanisms of activity through similarity of activity?
- Chemicals analyzed at single conc level to minimize polypharmacology effect
- Self Organizing Maps (SOM): 10X10 Array/100 Clusters
- Identify clusters enriched with chemicals with known activity
- Two examples:

Cluster	Cluster Count	Common Activity	Example Compounds known associations	Example Compounds novel associations
57,67	52	AhR ligands	Hydroquinone 4-Chloro-1,2-diaminobenzene 1,2-Phenylenediamine Fenaminosulf	C.I. Solvent yellow 14
48	27	ER pathway	Clomiphene citrate Tamoxifen citrate Fulvestrant Raloxifene Tamoxifen 4-Hydroxytamoxifen	Cyclopamine Amiodarone hydrochloride Haloperidol Reserpine Donated pharma: NK1 receptor antagonist Bradykinin B1 receptor antagonist Lipid-lowering agent


Hypothesis Generation Example

Blood coagulation *in vivo*




Use of Data in Predictive Modeling

- Combine all *in vitro* assay data following standardization/normalization—ToxCastDB
- Use *in vivo* data to anchor models—ToxRefDB
 - Holds *in vivo* endpoint data from animal toxicology studies
 - Currently at 5567 studies on 1049 unique chemicals



Data Source	Study Count
EPA OPP_der	3279
Open Literature	731
National Toxicol Program	666
Sanofi_pharma	222
Unpublished_submissions	50
GSK_pharma	38
Health Canada PMRA_der	23


Predictive Model Development from ToxCast and Other Data




Reproductive Rat Toxicity Model Features

Chemicals

Ordered By
ReproToxModelScore



Reproductive Rat Toxicity Model Features



Predictive Toxicity Modeling Based on ToxCast Data

❖ Predictive models: **endpoints**

liver tumors: Judson et al. 2010, Env Hlth Persp 118: 485-492

hepatocarcinogenesis: Shah et al. 2011, PLoS One 6(2): e14584

cancer: Kleinstreuer et al. 2013, Toxicol Sci 131:40-55.

rat fertility: Martin et al. 2011, Biol Reprod 85: 327-339

rat-rabbit prenatal devtox: Sipes et al. 2011, Toxicol Sci 124: 109-127

zebrafish vs ToxRefDB: Sipes et al. 2011, Birth Defects Res C 93: 256-267

❖ Predictive models: **pathways**

endocrine disruption: Reif et al. 2010, Env Hlth Persp 118: 1714-1720

microdosimetry: Wambaugh and Shah 2010, PLoS Comp Biol 6: e1000756

mESC differentiation: Chandler et al. 2011, PLoS One 6(6): e18540

HTP risk assessment: Judson et al. 2011, Chem Res Toxicol 24: 451-462

angiogenesis: Kleinstreuer et al. 2011, Env Hlth Persp 119: 1596-1603

❖ Continuing To Expand & Validate Prediction Models

❖ Generally moving towards more mechanistic/AOP-based models

Understanding Success and Failure

- Why *in vitro* to *in vivo* can work:
 - Chemicals cause effects through direct molecular interactions that we can measure with *in vitro* assays
- Why *in vitro* to *in vivo* does not always work:
 - Pharmacokinetics issues: biotransformation, clearance (FP, FN)
 - Assay coverage: don't have all the right assays (FN)
 - Tissue issues: may need multi-cellular networks and physiological signaling (FN)
 - Statistical power issues: need enough chemicals acting through a given MOA to be able to build and test model (FN)
 - Homeostasis: A multi-cellular system may adapt to initial insult (FP)
 - *In vitro* assays are not perfect! (FP, FN)
 - *In vivo* rodent data is not perfect! (FP, FN)

Summary

- **Methods developed to use *in vitro* assays to screen and prioritize many data-poor chemicals**
- **Signature generation uses combination of biological insight and statistics**
- **Public release of Phase II data will provide opportunity for others to analyze**
 - **Innocentive & TopCoder Challenges**
 - **data summit in Spring '14**
- **Further refinements are in the works**
 - **More chemicals and assays**
 - **Use of chemoinformatics**
 - **Systems-level models**
 - **Targeted testing approaches**

ACKNOWLEDGEMENTS:

❖ EPA/Office of Research and Development

- ❖ Matt Martin
- ❖ Richard Judson
- ❖ Jill Franzosa¹
- ❖ Shad Mosher
- ❖ Parth Kothiya¹
- ❖ Nisha Sipes
- ❖ Ann Richard
- ❖ Tom Knudsen
- ❖ Imran Shah
- ❖ Jimmy Phuong
- ❖ Nicole Kleinstreuer³
- ❖ Stephanie Padilla
- ❖ Samantha Frady
- ❖ David Reif²
- ❖ Daniel Rotroff²
- ❖ Kevin Crofton
- ❖ David Dix
- ❖ Robert Kavlock
- ❖ Amy Wang
- ❖ Rusty Thomas

1. ORISE
2. North Carolina State University
3. ILS, Inc.

❖ Bioseek/DiscoverX

- ❖ Ellen Berg
- ❖ Mark Polokov
- ❖ Jian Yang

❖ NIH/NCATS

- ❖ Menghang Xia
- ❖ Ruili Huang